How did revenue and profit move in opposite directions?

Revenue grew 43% to ₹382.87 crore, but net profit fell 19% to ₹6.82 crore. This means the cost of generating each rupee of revenue increased significantly.

Why is the Q4 result more alarming than the full-year?

Fourth-quarter profit fell 59% to ₹1.13 crore from ₹2.79 crore, a sharper drop than the full-year's 19% decline. This suggests the cost pressures intensified as the year went on.

What does this tell us about the business's scalability?

The filing shows the company is scaling sales but not profitability. Costs are rising faster than revenue, which is a warning sign about the sustainability of its growth model.

Earnings · Edible Oil · Micro cap

MK Proteins' 43% revenue jump can't stop profit from sliding

FY26 sales hit ₹382.87 crore, but net profit fell to ₹6.82 crore. The cost squeeze is accelerating, with Q4 profit down more than half.

— 1 earlier story on MK Proteins Ltd. →

MKPL By Tipsheet Editorial 29 May 2026 · 6:21 PM IST Verify on BSE · NSE

Mkt cap₹189 cr

P/E22.29×

ROE12.09%

Debt / eq.0.54

₹382.87 cr FY26 revenue, up 43% but with lower profit to show for it.

What's new

MK Proteins' annual revenue grew 43% to ₹382.87 crore for FY26.
Full-year net profit declined to ₹6.82 crore from ₹8.39 crore.
Q4 profit slumped to ₹1.13 crore from ₹2.79 crore a year earlier.

Why this matters

A 43% sales increase that still produces less profit is a clear sign of deteriorating unit economics. The problem got worse in the final quarter, where profit collapsed by 59%. For a nano-cap, this means growth is consuming capital, not generating it.

What we're watching

Whether the margin erosion continues into Q1 FY27.
Management commentary on raw material costs and pricing.
If the volume growth can outpace cost inflation.

The full read

MK Proteins grew revenue 43% to ₹382.87 crore in FY26. But it couldn't turn that into profit. Net profit fell 19% to ₹6.82 crore. The full-year number hides a worse trend. Q4 profit slumped to ₹1.13 crore from ₹2.79 crore, a 59% drop that signals the margin squeeze is accelerating. For a nano-cap, this is dangerous. The company is pouring resources into growth that isn't paying back. Sales are up, but each sale is worth less. The board re-appointed its auditors for FY27. The operational story is the one that matters.

Questions answered

How did revenue and profit move in opposite directions?: Revenue grew 43% to ₹382.87 crore, but net profit fell 19% to ₹6.82 crore. This means the cost of generating each rupee of revenue increased significantly.
Why is the Q4 result more alarming than the full-year?: Fourth-quarter profit fell 59% to ₹1.13 crore from ₹2.79 crore, a sharper drop than the full-year's 19% decline. This suggests the cost pressures intensified as the year went on.
What does this tell us about the business's scalability?: The filing shows the company is scaling sales but not profitability. Costs are rising faster than revenue, which is a warning sign about the sustainability of its growth model.

Mentioned: MK Proteins Ltd · ₹382.87 cr revenue · ₹6.82 cr net profit

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on MKPL →

29 May 2026 · 6:21 PM IST MK Proteins' 43% revenue jump can't stop profit from sliding
1d ago MK Proteins grew revenue 43%. Profit shrank anyway.